Glenmark Pharma Stocks Today, Glenmark Share Price Live Updates 11 July 2025: Shares of Glenmark Pharma in focus today.
Here’s why
Glenmark Pharma stock locked in upper circuit on the NSE at ₹2,094.40, higher by 10%. Its arm IGI Therapeutics SA & AbbVie, a global biopharmaceutical
company, announced an exclusive global licensing agreement for cancer and autoimmune drug ISB 2001.
- 09:46 | July 11, 2025
Glenmark Pharma Share price live today: Locked in upper circuit
Glenmark Pharma shares hit the upper circuit on the NSE, rising 10% to ₹2,094.40. The surge followed the announcement of an exclusive global licensing agreement between its subsidiary, IGI Therapeutics SA, and global biopharmaceutical giant AbbVie for the cancer and autoimmune drug ISB 2001.
- 09:45 | July 11, 2025
Glenmark share price live: Subsidiary IGI inks $700-m deal on cancer drug candidate with multinational AbbVie
Glenmark Pharmaceuticals’ wholly-owned subsidiary, Ichnos Glenmark Innovation Inc. (IGI), has entered into an exclusive licensing agreement with U.S.-based pharmaceutical company AbbVie for its lead drug candidate, ISB 2001. As part of the deal, IGI will receive an upfront payment of $700 million (approximately ₹6,000 crore).
Published on July 11, 2025